Article Details

Gilead Q4 Earnings Highlights: Remdesivir Sales Fall 30%, Raises Dividend, FY22 EPS ...

Retrieved on: 2022-02-02 11:19:53

Tags for this article:

Click the tags to see associated articles and topics

Gilead Q4 Earnings Highlights: Remdesivir Sales Fall 30%, Raises Dividend, FY22 EPS .... View article details on hiswai:

Excerpt

Veklury (remdesivir 100 mg for injection) product sales declined 30% Y/Y to $1.4 billion, generally affected by COVID-19 related rates of ...

Article found on: www.benzinga.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up